JP2021532165A5 - - Google Patents

Info

Publication number
JP2021532165A5
JP2021532165A5 JP2021510499A JP2021510499A JP2021532165A5 JP 2021532165 A5 JP2021532165 A5 JP 2021532165A5 JP 2021510499 A JP2021510499 A JP 2021510499A JP 2021510499 A JP2021510499 A JP 2021510499A JP 2021532165 A5 JP2021532165 A5 JP 2021532165A5
Authority
JP
Japan
Prior art keywords
formula
compound represented
diseases
crystalline
forms
Prior art date
Application number
JP2021510499A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019210511A5 (https=
JP2021532165A (ja
JP7275253B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2018/085617 external-priority patent/WO2019210511A1/zh
Publication of JP2021532165A publication Critical patent/JP2021532165A/ja
Publication of JPWO2019210511A5 publication Critical patent/JPWO2019210511A5/ja
Publication of JP2021532165A5 publication Critical patent/JP2021532165A5/ja
Priority to JP2023023091A priority Critical patent/JP7651198B2/ja
Application granted granted Critical
Publication of JP7275253B2 publication Critical patent/JP7275253B2/ja
Priority to JP2025035420A priority patent/JP2025074350A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510499A 2018-05-04 2018-05-04 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 Active JP7275253B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023023091A JP7651198B2 (ja) 2018-05-04 2023-02-17 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
JP2025035420A JP2025074350A (ja) 2018-05-04 2025-03-06 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/085617 WO2019210511A1 (zh) 2018-05-04 2018-05-04 一种s1p1受体激动剂的加成盐及其晶型和药物组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023023091A Division JP7651198B2 (ja) 2018-05-04 2023-02-17 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物

Publications (4)

Publication Number Publication Date
JP2021532165A JP2021532165A (ja) 2021-11-25
JPWO2019210511A5 JPWO2019210511A5 (https=) 2022-07-08
JP2021532165A5 true JP2021532165A5 (https=) 2022-07-08
JP7275253B2 JP7275253B2 (ja) 2023-05-17

Family

ID=68387039

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021510499A Active JP7275253B2 (ja) 2018-05-04 2018-05-04 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
JP2023023091A Active JP7651198B2 (ja) 2018-05-04 2023-02-17 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
JP2025035420A Pending JP2025074350A (ja) 2018-05-04 2025-03-06 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023023091A Active JP7651198B2 (ja) 2018-05-04 2023-02-17 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
JP2025035420A Pending JP2025074350A (ja) 2018-05-04 2025-03-06 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物

Country Status (13)

Country Link
US (3) US11512078B2 (https=)
EP (2) EP4353719B1 (https=)
JP (3) JP7275253B2 (https=)
KR (2) KR20240094023A (https=)
AU (1) AU2018421487B2 (https=)
CA (1) CA3099196A1 (https=)
ES (1) ES2978392T3 (https=)
IL (3) IL312512B2 (https=)
MX (1) MX2020011665A (https=)
NZ (1) NZ770323A (https=)
SG (1) SG11202010969UA (https=)
WO (1) WO2019210511A1 (https=)
ZA (1) ZA202007347B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ770323A (en) * 2018-05-04 2025-12-19 Suzhou Connect Biopharmaceuticals Ltd Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
WO2022099155A1 (en) * 2020-11-09 2022-05-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
CN103450171B (zh) 2013-09-22 2015-07-08 苏州康乃德生物医药有限公司 一种免疫调节化合物、其用途和包含其的药物组合物
CN105315266B (zh) * 2014-08-01 2019-10-01 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型
CN105348276B (zh) 2014-08-22 2020-05-26 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法
CN112778290B (zh) 2017-01-11 2022-12-06 苏州康乃德生物医药有限公司 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
NZ770323A (en) * 2018-05-04 2025-12-19 Suzhou Connect Biopharmaceuticals Ltd Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition

Similar Documents

Publication Publication Date Title
JP2020033360A5 (https=)
JP2018518537A5 (https=)
JP2018513188A5 (https=)
JP2021525729A5 (https=)
JP2019520344A5 (https=)
JP2021512906A5 (https=)
JP2022507533A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
JP2015508765A5 (https=)
JP2021532165A5 (https=)
JP2016528171A5 (https=)
JP2013536206A5 (https=)
JP5745526B2 (ja) 糖尿病の予防のためのスルホンアミド
AU2019336248A1 (en) New use of R-enantiomer of adrenergic β2 receptor agonists for treatment of inflammatory bowel disease and its extra intestinal manifestations
JP2020535139A (ja) シポニモドの投与レジメン
KR102635938B1 (ko) 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
Iversen Late results from continuous treatment of thyrotoxicosis with methylthiouracil
JP6454436B1 (ja) ペマフィブラートを含有する医薬
CN114588164B (zh) 瑞马唑仑在预防围术期低体温和寒战中的应用
JPH01265027A (ja) 肝疾患治療剤
JPWO2019210511A5 (https=)
JP7408643B2 (ja) カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用
KR20190013847A (ko) 불안 장애를 치료하기 위한 (2S)-1-[4-(3,4-디클로로페닐)피페리딘-1-일]-3-[2-(5-메틸-1,3,4-옥사디아졸-2-일)벤조[b]푸란-4-일옥시]프로판-2-올 또는 그의 대사산물
CN109758453A (zh) 胺类化合物治疗焦虑障碍的医药用途
JP6188784B2 (ja) 炎症性および免疫性疾患の治療のための組成物
JPH10175852A5 (https=)